Literature DB >> 21850662

Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.

Tariq I Mughal1, Jerald P Radich, Richard A Van Etten, Alfonso Quintás-Cardama, Tomasz Skorski, Farhad Ravandi, Daniel J DeAngelo, Carlo Gambacorti-Passerini, Giovanni Martinelli, Ayalew Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21850662      PMCID： PMC3485684          DOI： 10.1002/ajh.22097

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  94 in total

1.  Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol.

Authors:  Marco Vignetti; Paola Fazi; Giuseppe Cimino; Giovanni Martinelli; Francesco Di Raimondo; Felicetto Ferrara; Giovanna Meloni; Achille Ambrosetti; Giovanni Quarta; Livio Pagano; Giovanna Rege-Cambrin; Loredana Elia; Raffaello Bertieri; Luciana Annino; Robin Foà; Michele Baccarani; Franco Mandelli
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

2.  BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.

Authors:  M Koptyra; K Cramer; A Slupianek; C Richardson; T Skorski
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

Review 3.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

4.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

5.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

Review 6.  Mechanisms of resistance to BCR-ABL kinase inhibitors.

Authors:  Joana M Diamond; Junia V Melo
Journal:  Leuk Lymphoma       Date:  2011-02

Review 7.  DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis.

Authors:  Carol Bernstein; Harris Bernstein; Claire M Payne; Harinder Garewal
Journal:  Mutat Res       Date:  2002-06       Impact factor: 2.433

8.  Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Authors:  Neil P Shah; Hagop M Kantarjian; Dong-Wook Kim; Delphine Réa; Pedro E Dorlhiac-Llacer; Jorge H Milone; Jorge Vela-Ojeda; Richard T Silver; H Jean Khoury; Aude Charbonnier; Nina Khoroshko; Ronald L Paquette; Michael Deininger; Robert H Collins; Irma Otero; Timothy Hughes; Eric Bleickardt; Lewis Strauss; Stephen Francis; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

9.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

10.  Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.

Authors:  Gianantonio Rosti; Francesca Palandri; Fausto Castagnetti; Massimo Breccia; Luciano Levato; Gabriele Gugliotta; Adele Capucci; Michele Cedrone; Carmen Fava; Tamara Intermesoli; Giovanna Rege Cambrin; Fabio Stagno; Mario Tiribelli; Marilina Amabile; Simona Luatti; Angela Poerio; Simona Soverini; Nicoletta Testoni; Giovanni Martinelli; Giuliana Alimena; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani
Journal:  Blood       Date:  2009-10-12       Impact factor: 22.113
View more
  1 in total

1.  Identification of potential therapeutic target genes and miRNAs for primary myelofibrosis with microarray analysis.

Authors:  Yong Liu; Bo Wei; Xuebing Zhang; Dehui Xu; Bo Wang; Guochao Yin; Dawer Gu; Yuxiang Li; Daliang Kong
Journal:  Exp Ther Med       Date:  2017-08-09       Impact factor: 2.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.